Board of Visitors leadership welcomes new...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance the institution’s mission to end cancer, marks the beginning of Fiscal Year 2019 with nine new members, effective Sept. 1:
Combination immunotherapy shrinks melanoma brain metastases
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported...
PARP inhibitor improves progression-free survival in patients with...
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor...
MD Anderson ranked No. 1 for cancer care in national survey
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual...
MD Anderson and Jazz Pharmaceuticals collaborate to evaluate...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement...
Comprehensive CAR T-cell therapy pediatric guidelines developed by...
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for...